Evidence map›Paper›PMID 41214566›Full record

SynthesisBMC cancer2025

Investigating the prognostic value of non-coding RNAs in chronic lymphocytic leukemia: insights from a systematic review and meta-analysis.

Amir Hossein Aghayan, Ali Arab, Shadi Haddadi, Yasin Mirazimi, Ali Hosseinzadeh, Tayebeh Mohtashami, Amir Atashi

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amir Hossein AghayanStudent Research Committee, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran.
Ali ArabDepartment of Pharmacology and Toxicology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
Shadi HaddadiDepartment of Pharmacology and Toxicology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
Yasin MirazimiStudent Research Committee, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran.
Ali HosseinzadehDepartment of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.
Tayebeh MohtashamiStudent Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Amir AtashiDepartment of Medical Laboratory Sciences, School of Allied Medical Sciences, Shahroud University of Medical Sciences, Shahroud, Iran. atashia@shmu.ac.ir.

Funding

National Institute for Medical Research Development 4021137
6 · The paper itself

Abstract

backgroundNon-coding RNA (ncRNA) expression dysregulation has been implicated in the prognosis of various cancers. Several mechanisms have been associated with altered expression of the ncRNAs with the progression of chronic lymphocytic leukemia (CLL). Based on the special properties that ncRNAs possess, including their stability, tissue specificity, and disease-associated dysregulation, a considerable amount of research has been conducted to identify their potential as non-invasive prognostic biomarkers.

methodsA comprehensive search was conducted in WOS, Scopus, PubMed, Embase, and ProQuest, in accordance with PRISMA guidelines. Hazard ratios (HRs) were used to assess the prognostic value of ncRNA dysregulation in CLL. Risk of bias was evaluated with the QUIPS tool, and subgroup analyses were based on sample size and study quality. Publication bias was assessed using Egger’s, Begg’s, and Trim-and-Fill tests. Sensitivity analysis employed the leave-one-out method, and evidence certainty was graded using the modified GRADE framework.

resultsOur analysis included 4905 CLL patients. Dysregulated miRNAs were associated with shorter overall survival (OS) (HR: 2.41), progression-free survival (PFS) (HR: 1.82), and time to treatment (TTT) (HR: 2.39) in CLL patients. Dysregulation of lncRNAs was linked to poorer OS (HR: 2.76) and earlier TTT initiation (HR: 2.53). Additionally, dysregulation of circRNAs was associated with poorer OS (HR: 3.91).

conclusionOur comprehensive meta-analysis results showed that dysregulation of ncRNAs, including miRNAs, lncRNAs, and circRNAs, was associated with poor clinical outcomes in parameters such as OS, PFS, and TTT, identifying them as moderate prognostic markers for CLL patients.

Indexed as

Biomarkers, TumorLeukemia, Lymphocytic, Chronic, B-CellRNA, UntranslatedGene Expression Regulation, NeoplasticHumansMicroRNAsPrognosisRNA, Long NoncodingBiomarkers, TumorMicroRNAsRNA, Long NoncodingRNA, UntranslatedCircRNAsLong noncoding RNAMicroRNANon-coding RNAsOverall survivalProgression-free survivalTime to treatment

Identifiers

PMID41214566
PMCPMC12604295

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.